NanoVibronix Q4 2023 revenue $1.2M record; CMS reimbursement still not approved

ENvue Medical, Inc.

Q4 2023 revenue of $1.2M (record quarter); loss from operations of $702K.
Cash of $3.3M, inventory $2.7M; raised $4.2M net in Q3 2023.
CMS reimbursement for PainShield still not approved; efforts continue.
University of Michigan to initiate UroShield RCT (pilot 30, full study 300+).
Selected engineering partner for next-gen product development expected Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.